George Reiss, MD
Ophthalmology · Glendale, AZNPI 1619927969
Payments from drug & device makers
Across 578 payments — averaging $2185.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$1M
- AbbVie$154K
- Alcon Research LLC$20K
- Aerie Pharmaceuticals, Inc.$20K
- W. L. Gore & Associates, Inc.$14K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
- plus $5K from 15 others
Across 3 payments — averaging $812.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$2K
- AbbVie$285
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 307 | $1,044,689 |
| AbbVie(2 entities) | 94 | $153,850 |
| Alcon Research LLC | 16 | $20,338 |
| Aerie Pharmaceuticals, Inc. | 45 | $20,152 |
| W. L. Gore & Associates, Inc. | 19 | $13,955 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $5,123 |
| Nova Eye, Inc. | 4 | $1,713 |
| Carl Zeiss Meditec USA, Inc. | 8 | $1,245 |
| Alcon | 28 | $798 |
| Bausch & Lomb Americas Inc. | 13 | $339 |
| Novartis | 5 | $192 |
| Sight Sciences, Inc. | 3 | $188 |
| Ocular Therapeutix, Inc. | 2 | $160 |
| Rxsight Inc | 2 | $155 |
| NEW World Medical,inc. | 8 | $133 |
| Imperative Care, Inc | 1 | $96 |
| Dompe US, Inc. | 1 | $95 |
| Ivantis, Inc | 2 | $71 |
| Thea Pharma Inc. | 2 | $34 |
| Kala Pharmaceuticals, Inc. | 2 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
How this compares
$1,263,378 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Glendale
- Shamil PatelGlendale$457K
- Sara GhobraielGlendale$345K
- Wendy HuangGlendale$73K
- Anne FloydGlendale$11K
- Mark BarakatScottsdale$2.9M
- Michael DepenbuschChandler$2.3M
- Ramin SchadluPhoenix$1.8M
- Gerald WalmanSun City$1.7M
- John CasonPhoenix$1.7M
- Warren HillMesa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.